Why Dyne Therapeutics Stock Was a Big Winner on Wednesday

Dyne Therapeutics (NASDAQ: DYN) stock stood apart from its biotech peers on Hump Day, posting a meaty share price gain across the trading session. On the back of an analyst's upgrade, accompanied by a significant price target raise, investors piled into the stock to lift it to a nearly 7% increase. The person behind the upgrade was Jay Olson of Oppenheimer. Before market open, he changed his recommendation on Dyne stock to outperform (buy, in other words) from his previous perform (hold). He also nearly quadrupled his price target on the shares, to $40 apiece from $11. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool